An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 852, Issue 1-2, 2007, Pages 174-179

  Kim, Sung Su ^a   Im, Ho Taek ^a   Kang, Il Mo ^a   Lee, Hyun Su ^a   Lee, Heon Woo ^a   Cho, Sung Hee ^a   Kim, Jong Bin ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Bioequivalence; Fluconazole; High performance liquid chromatography (HPLC); Human plasma; Validation

Indexed keywords

CONCENTRATION (PROCESS); DICHLOROMETHANE; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN); ULTRAVIOLET DETECTORS;

BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; FLUCONAZOLE; LINEAR CONCENTRATION; LIQUID-LIQUID EXTRACTION;

AROMATIC COMPOUNDS;

DICHLOROMETHANE; FLUCONAZOLE;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KOREA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TABLET; ULTRAVIOLET RADIATION;

ADULT; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUCONAZOLE; HUMANS; MALE; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; THERAPEUTIC EQUIVALENCY;

EID: 34249717358     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.01.012     Document Type: Article

References (20)

1. de With K., Steib-Bauert M., Knoth H., Dorje F., Strehl E., Rothe U., Maier L., and Kern W.V. BMC Clin. Pharmacol. 5 (2005) 1
2. Bennets J.E. In: Blanton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics (2006), McGraw-Hill, New York 1225
3. Humphrey M.J., Jevons S., and Tarbit M.H. Antimicrob. Agents Chemother. 28 (1985) 648
4. Wood P.R., and Tarbit M.H. J. Chromatogr. 383 (1986) 179
5. Moraes L.A., Lerner F.E., Moraes M.E., Moraes M.O., Corso G., and De Nucci G. Ther. Drug Monit. 21 (1999) 200
6. Pereira R., Fidelis S., Vanunci M.L., Oliveira C.H., Mendes G.D., Abib E., and Moreno R.A. Int. J. Clin. Pharmacol. Ther. 42 (2004) 39
7. Hosotsubo K.K., Hosotsubo H., Nishijima M.K., Okada T., Taenaka N., and Yoshiya I. J. Chromatogr. 529 (1990) 223
8. Manorot M., Rojanasthien N., Kumsorn B., and Teekachunhatean S. Int. J. Clin. Pharmacol. Ther. 38 (2000) 355
9. Majcherczyk P.A., Moreillon P., Decosterd L.A., Sanglard D., Bille J., Glauser M.P., and Marchetti O. J. Pharm. Biomed. Anal. 28 (2002) 645
10. Egle H., Trittler R., and Kummerer K. Ther. Drug Monit. 26 (2004) 425
11. Al-Gaai E., Lockyer M., Al-Digither S., and Hammami M.M. Biopharm. Drug Dispos. 26 (2005) 143
12. Porta V., Chang K.H., and Storpirtis S. Int. J. Pharm. 288 (2005) 81
13. Wattananat T., and Akarawut W. Biomed. Chromatogr. 20 (2006) 1
14. Inagaki K., Takagi J., Lor E., Okamoto M.P., and Gill M.A. Ther. Drug Monit. 14 (1992) 306
15. Koks C.H., Rosing H., Meenhorst P.L., Bult A., and Beijnen J.H. J. Chromatogr. B Biomed. Appl. 663 (1995) 345
16. Jovanovic D., Kilibarda V., Ciric B., Vucinic S., Srnic D., Vehabovic M., and Potogija N. Clin. Ther. 27 (2005) 1588
17. FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001, http://www.fda.gov/cder/guidance/index.htm.
18. Lee Y.J., Kim Y.G., Lee M.G., Chung S.J., Lee M.H., and Shim C.K. Yakhakhoeji 44 (2000) 308
19. KFDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, Bioequivalence Division, Pharmacology Department, National Institute of Toxicology Department, 2003, http://ezdrug.kfda.go.kr/kfda2.
20. FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001, http://www.fda.gov/cder/guidance/index.htm.